Health
Compounded and Counterfeit Semaglutide: What the FDA Is Warning About
Shortages pushed patients toward compounded semaglutide. The FDA's latest alert shows why that workaround carries real risk.
Aug 5, 2024
Loading
Search
Results
12 stories for“semaglutide fda approval”
Health
Ozempic and Wegovy: What the Trials Actually Showed
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024
Health
GLP-1 Drugs Are Becoming More Than Weight Loss Medicine
Tirzepatide just earned an approval that has nothing to do with the scale. Here is what SELECT, FLOW and the new sleep apnea data show.
Jan 8, 2025
Health
An FDA Panel Just Backed Compounded BPC-157. That Is Not the Same as Approval
On 23 and 24 July, an FDA advisory committee looked at seven peptides and recommended that pharmacies be allowed to compound several of them. The vote is not binding, and the evidence gap has not moved.
Aug 11, 2026
Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Health
GLP-1 Side Effects and Who Should Not Take Them
Nausea is the least of it. Here is an honest look at GLP-1 side effects, the thyroid warning, pancreatitis and who is advised to avoid them.
Jul 10, 2024
Health
The GLP-1 Era: How Weight-Loss Drugs Changed Us
Semaglutide and tirzepatide went from diabetes treatment to celebrity shortcut to a genuine health story. What happens when one drug becomes a cultural moment.
Apr 20, 2024
Health
What a Peptide Actually Is, and Why the Word Now Sells Almost Anything
Insulin is a peptide. So is Ozempic. So is the unlabelled vial someone is selling on Telegram. The word describes a chemical class, not a level of evidence, and that gap is where the market lives.
Aug 11, 2026
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Health
What Is Actually in a Grey-Market Peptide Vial
Research use only is a legal phrase, not a quality standard. Testing of peptides bought online keeps finding the wrong dose, the wrong compound, or contamination in something people inject at home.
Aug 12, 2026
